GastroenterologyNews.net

Gastroenterology Xagena

Search results for "Humira"

A Phase III study showed that patients with moderate to severely active Crohn's disease treated with Adalimumab ( Humira ) have seen continuing improvements in clinical response and clinical remissio ...


IBD ( inflammatory bowel diseases ) is a term referring to several chronic diseases that cause inflammation of the intestines, including ulcerative colitis and Crohn's disease. Symptoms for both con ...


The results from a study showing patients with moderate to severely active Crohn's disease treated with Adalimumab ( Humira ) were more likely to maintain clinical remission through one year than pati ...


Safe, effective treatment options exist for patients with mild-to-moderate Crohn’s disease or ulcerative colitis. However, a significant proportion of patients with moderate-to-severe Crohn’s disease ...


Optimizing anti-tumor necrosis factor therapy is often required in patients with Crohn's disease. In case of partial response or loss of response to Adalimumab ( Humira ) 40 mg every other week, the i ...


Adalimumab ( Humira ) is the key treatment for ulcerative colitis unresponsive or intolerant to standard treatments. The aim of the study was to assess the efficacy and safety of Adalimumab in treatin ...


The safety and efficacy of Adalimumab ( Humira ) for patients with moderately to severely active ulcerative colitis has been reported up to week 52 from the placebo-controlled trials ULTRA ( Ulcerativ ...


Information on efficacy and predictors of response to Adalimumab ( Humira ) in ulcerative colitis clinical practice is limited. The aim of study was assessed the response to Adalimumab and its pred ...


Adalimumab ( Humira ) is effective for induction and maintenance of remission in patients with moderate to severe ulcerative colitis. Researchers have assessed whether Adalimumab, in addition to sta ...


The efficacy of Adalimumab ( Humira ) in children with moderately to severely active Crohn’s disease enrolled in the IMAgINE 1 trial has been reported up to week ( wk ) 52. Long-term efficacy of Adali ...


TNF inhibitors are effective in the treatment of ulcerative colitis. Adalimumab ( Humira ), a fully human TNF inhibitor, is increasingly used both as primary anti-TNF agent and in patients switching f ...


The objective of the present study was to evaluate the effectiveness and safety of Adalimumab ( Humira ) in children with Crohn disease ( CD ) who experienced Infliximab ( Remicade ) failure at the po ...


Data about the effectiveness of biologics, including anti-tumor necrosis factor ( anti-TNF ) therapy and anti-integrin strategies, in antibiotic refractory pouchitis or Crohn's disease-associated pouc ...


Endoscopic healing and clinical remission are important parameters to evaluate therapeutic efficacy in Crohn's disease. The aim of a study was to investigate the clinical effectiveness of Adalimumab ...


Infliximab ( Remicade ) has been shown to have beneficial effects on bone metabolism in patients with Crohn's disease ( CD ) although as yet the exact mechanisms have not been fully elucidated. A s ...